Related references
Note: Only part of the references are listed.RESTORE-IMI 1: A Multicenter, Randomized, Double-blind Trial Comparing Efficacy and Safety of Imipenem/Relebactam vs Colistin Plus Imipenem in Patients With Imipenem-nonsusceptible Bacterial Infections
Johann Motsch et al.
CLINICAL INFECTIOUS DISEASES (2020)
Pharmacokinetics, Safety, and Tolerability of Single and Multiple Doses of Relebactam, a beta-Lactamase Inhibitor, in Combination with Imipenem and Cilastatin in Healthy Participants
Elizabeth G. Rhee et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2018)
Prospective, randomized, double-blind, Phase 2 dose-ranging study comparing efficacy and safety of imipenem/cilastatin plus relebactam with imipenem/cilastatin alone in patients with complicated urinary tract infections
Matthew Sims et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2017)
Phase 2, Dose-Ranging Study of Relebactam with Imipenem-Cilastatin in Subjects with Complicated Intra-abdominal Infection
Christopher Lucasti et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2016)
Antimicrobial-Resistant Pathogens Associated With Healthcare-Associated Infections: Summary of Data Reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2011-2014
Lindsey M. Weiner et al.
INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY (2016)
Healthcare utilization and costs associated with S-aureus and P-aeruginosa pneumonia in the intensive care unit: a retrospective observational cohort study in a US claims database
Moe H. Kyaw et al.
BMC HEALTH SERVICES RESEARCH (2015)
Demography and burden of care associated with patients readmitted for urinary tract infection
Shawn H. MacVane et al.
JOURNAL OF MICROBIOLOGY IMMUNOLOGY AND INFECTION (2015)
Interethnic Differences in Pharmacokinetics of Antibacterials
Danny Tsai et al.
CLINICAL PHARMACOKINETICS (2015)
Discovery of MK-7655, a β-lactamase inhibitor for combination with Primaxin®
Timothy A. Blizzard et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2014)
Complicated intra-abdominal infections worldwide: the definitive data of the CIAOW Study
Massimo Sartelli et al.
WORLD JOURNAL OF EMERGENCY SURGERY (2014)
Deaths Attributable to Carbapenem-Resistant Enterobacteriaceae Infections
Matthew E. Falagas et al.
EMERGING INFECTIOUS DISEASES (2014)
Activity of MK-7655 combined with imipenem against Enterobacteriaceae and Pseudomonas aeruginosa
David M. Livermore et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2013)
The role of ethnicity in variability in response to drugs: Focus on clinical pharmacology studies
S. U. Yasuda et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2008)
In vitro susceptibilities of aerobic and facultatively anaerobic Gram-negative bacilli isolated from patients with intra-abdominal infections worldwide:: 2004 results from SMART (Study for Monitoring Antimicrobial Resistance Trends)
Flavia Rossi et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2006)